BOSTON, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the Company will participate in two upcoming investor conferences. Jefferies Global Healthcare Conference in LondonDipal Doshi, Chief Executive Officer, will deliver a company presentation on Tuesday, November 18, 2025, at 5:00 p.m. Greenwich Mean Time in London. 8th Annual Evercore Healthcare ConferenceDipal Doshi, Chief Executive Officer, will participate in a fireside chat on Wednesday, December 3, 2025, a ...

BEDFORD, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that it plans to host a conference call and webcast on Tuesday, November 4, 2025 at 8:00 AM ET to discuss recent business progress and financial results for the third quarter ended September 30, 2025. Conference Call and Webcast Information: Date: Tuesday, November 4, 2025, at 8:00 AM ET Participant Dial-In ...

AC Immune Appoints Renowned Neurologist Catherine Mummery as Chair of Clinical Advisory Board Brings substantial expertise in development of first-in-class disease-modifying therapies in dementia across multiple novel modalitiesIncludes immunotherapies and small molecule drugs targeting intracellular proteinopathiesLeadership in groundbreaking early-stage clinical trials reinforces Company’s competencies Lausanne, Switzerland, October 28, 2025 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceut ...

Core Insights - BioMarin Pharmaceuticals (NASDAQ: BMRN) shares have been underperforming, currently trading at their lowest levels since 2013, indicating significant challenges for the company [1] Group 1 - The company is a large biopharmaceutical entity that does not pay dividends, which exacerbates the negative impact of its stock performance [1] - The investing group "Value In Corporate Events" focuses on identifying opportunities in major corporate events such as IPOs, mergers & acquisitions, and earnings reports, providing coverage of 10 significant events monthly [1]

Third quarter 2025 revenues increased 1% to $3.75 billion versus third quarter 2024Dupixent® global net sales (recorded by Sanofi) increased 27% to $4.86 billion EYLEA HD® U.S. net sales increased 10% to $431 million; total EYLEA HD and EYLEA® U.S. net sales decreased 28% to $1.11 billion GAAP EPS of $13.62 and non-GAAP EPS(a) of $11.83; third quarter 2025 includes unfavorable $0.68 impact from acquired IPR&D chargeFDA approved Libtayo® as the first and only immunotherapy for high-risk adjuvant cutaneous sq ...

Core Insights - Karolinska Development AB has invested SEK 7.5 million in BOOST Pharma's financing round, which totals SEK 15 million, aimed at advancing the clinical development of BT-101 for osteogenesis imperfecta [1][3][4] Company Overview - BOOST Pharma is a clinical-stage biopharmaceutical company focused on developing BT-101, a mesenchymal stem cell therapy for infants with osteogenesis imperfecta, a condition that leads to fragile bones and frequent fractures [2][3] - The financing will help BOOST Pharma accelerate its clinical program and work towards providing the first disease-modifying therapy for osteogenesis imperfecta [2] Clinical Development - Following positive results from the Phase 2 BOOSTB4 study, which showed a reduction in fracture rate of over 75% in children treated with BT-101, BOOST Pharma is preparing for a pivotal Phase 3 trial [3] - The BOOSTB4 trial demonstrated that BT-101 was safe and well-tolerated [3] Investment and Ownership - Karolinska Development holds a 14% ownership stake in BOOST Pharma, reflecting its commitment to supporting the development of innovative therapies [4]

Core Insights - Karolinska Development AB has invested SEK 7.5 million in BOOST Pharma's financing round, which totals SEK 15 million, aimed at advancing the clinical development of BT-101 for osteogenesis imperfecta [1][3][4] Company Overview - BOOST Pharma is a clinical-stage biopharmaceutical company focused on developing BT-101, a mesenchymal stem cell therapy for infants with osteogenesis imperfecta, a condition that leads to fragile bones and frequent fractures [2][3] - The financing will help BOOST Pharma accelerate its clinical program and work towards providing the first disease-modifying therapy for osteogenesis imperfecta [2] Clinical Development - Following positive results from the Phase 2 BOOSTB4 study, which demonstrated a reduction in fracture rate of over 75% in children with osteogenesis imperfecta, BOOST Pharma is preparing for a pivotal Phase 3 trial of BT-101 [3] - The BOOSTB4 trial indicated that BT-101 was safe and well-tolerated [3] Investment and Ownership - Karolinska Development's ownership stake in BOOST Pharma is 14% [4] - The financing round included equal participation from Industrifonden and Karolinska Development, highlighting collaborative investment efforts in the biopharmaceutical sector [3]

Core Points - The meeting is the 2025 Annual General Meeting of CSL, emphasizing the company's commitment to starting on time [2] - A video presentation features a patient, Melissa, who has hereditary angioedema (HAE), highlighting the effectiveness of CSL's products in managing her condition [2] - CSL's annual report is available for further insights into the company's purpose and its impact on patients' lives [3]

Sanofi successfully prices USD 3 billion of bond issue Paris, France – October 28, 2025 - Sanofi announces that it has successfully priced its offering of $3 billion of notes across 5 tranches: $400 million fixed rate notes, due November 2027, bearing interest at a rate of 3.75%. $500 million floating rate notes, due November 2027, bearing interest at compounded SOFR plus 0.46%. $400 million fixed rate notes, due November 2028, bearing interest at a rate of 3.80%. $500 million floating rate notes, due No ...

CSL Limited (ASX:CSL) has tumbled nearly -15% in the first hour of Tuesday trades after the market balked at its latest AGM, particularly news that the Australian company expects the influenza vaccination rate in the U.S. to decline -12%.Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout the week. On Spotify, Apple, and more. That decline will see revenues from that segment decline by a number ‘in the mid-teens,’ CSL confirmed on Tuesday, a wor ...